Pelthos Therapeutics Inc. 8-K

What Happened

• On April 14, 2026 Pelthos Therapeutics Inc. filed a Form 8-K (Regulation FD disclosure) announcing that CEO Scott Plesha will participate in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium in Boston on April 16, 2026.
• The company furnished a press release as Exhibit 99.1 and posted a corporate presentation (attached as Exhibit 99.2); the filing notes that website content is not incorporated by reference into the 8-K.

Key Details

• CEO: Scott Plesha will be meeting with investors on April 16, 2026.
• Event: Piper Sandler Spring Biopharma Symposium, Boston, Massachusetts.
• Filing date: Form 8-K submitted April 14, 2026 and signed by CFO John M. Gay.
• Materials: Press release (Exhibit 99.1) and company presentation (Exhibit 99.2) were made available.

Why It Matters

• Management access: One-on-one meetings give investors direct access to the CEO for updates and Q&A, which can improve transparency and investor relations.
• No financial or operational results were disclosed in this filing—investors should review the attached press release and presentation for any substantive updates and watch for future filings or public statements for material changes.